Axsome Therapeutics (AXSM) Accounts Payables (2015 - 2026)

Axsome Therapeutics has reported Accounts Payables for 12 years, with the latest figure at $106.7 million in Q1 2026.

• Quarterly Accounts Payables rose 24.57% year-over-year to $106.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.7 million (up 24.57% YoY) and the FY2025 annual result came in at $65.5 million, down 8.97% from the prior year.
• Accounts Payables rose to $106.7 million in Q1 2026 per AXSM's latest filing, from $65.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $106.7 million in Q1 2026 and troughed at $12.6 million in Q1 2022.
• A 5-year average of $52.2 million and a median of $53.8 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 193.59% in 2022, then decreased 15.6% in 2025.
• Over 5 years, Accounts Payables stood at $38.6 million in 2022, then increased by 5.37% to $40.7 million in 2023, then jumped by 76.99% to $72.0 million in 2024, then fell by 8.97% to $65.5 million in 2025, then jumped by 62.81% to $106.7 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $106.7 million, $65.5 million, and $54.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.